Anida Pharma
PrivateLast Round
Seed
Dec 21, 2020
Company Overview
Anida Pharma is a biotechnology company developing a pipeline of ocular therapies to prevent and slow the progression of corneal and retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Anida Pharma Comparables
Compare Anida Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exonate | 84% | |
| Retinset, S.L. | 84% | |
| OcuTerra Therapeutics | 82% | |
Anida Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Dec 21, 2020 | ||||
| Grant | Sep 27, 2013 |
Anida Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 3, 2026
Monthly visitors grew 107% MoM.
- Nov 8, 2025
Monthly visitors grew 487% MoM, from 329 to 1.9K.
Anida Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Anida Pharma's valuation, stock price, and market status.